Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies-Reference-Cited by-同舟云学术

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

Published:2014-08-07 Issue:1 Volume:94 Page:23-34
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Oosterveld Margriet,Suciu Stefan,Muus Petra,Germing Ulrich,Delforge Michel,Belhabri Amin,Aul Carlo,Selleslag Dominik,Ferrant Augustin,Marie Jean-Pierre,Amadori Sergio,Jehn Ulrich,Mandelli Franco,Hess Uwe,Hellström-Lindberg Eva,Cakmak-Wollgast Songuel,Vignetti Marco,Labar Boris,Willemze Roel,de Witte Theo

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-014-2177-y.pdf

Reference57 articles.

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199

2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620–625

3. Kahl C, Florschutz A, Muller G, Jentsch-Ullrich K, Arland M, Leuner S, Franke A, Hoffkes HG (1997) Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol 75:91–94

4. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193–207

5. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217–223

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in an observational study: The JALSG-CS11-MDS-SCT;Annals of Hematology;2023-11-08

2. Outcomes of transplant-eligible patients with myelodysplastic syndrome with excess blasts registered in a prospective observational study: The JALSG-CS11-MDS-SCT;2022-11-18

3. A phase I clinical trial to study the safety of treatment with tipifarnib combined with bortezomib in patients with advanced stages of myelodysplastic syndrome and oligoblastic acute myeloid leukemia;Leukemia Research;2021-06

4. Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome;Hematopoietic Cell Transplantation for Malignant Conditions;2019

5. Long-term outcome of high risk patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving intensive chemotherapy;Annals of Hematology;2018-08-04